Back

In silico Exploration Natural Compounds for the Discovery of Novel DNMT3A Inhibitors as Potential Therapeutic Agents for Acute Myeloid Leukemia

Das, U.; Uttarkar, A.; Kumar, J.; Niranjan, V.

2024-08-29 bioinformatics
10.1101/2024.08.28.610083 bioRxiv
Show abstract

Aberrant DNA methylation, a hallmark of acute myeloid leukemia (AML), is catalyzed by DNA methyltransferase 3A (DNMT3A). Approximately 20-30% of AML patients harbor DNMT3A mutations, leading to disrupted DNA methylation patterns and leukemogenesis. To identify potential therapeutic interventions, this study employed computational drug discovery. A pharmacophore model was constructed and utilized to screen a natural product database, yielding a set of promising compounds. Subsequent molecular docking, MM-GBSA calculations, and ADMET profiling identified two compounds, CNP0375130 and CNP0256178, as potential DNMT3A inhibitors. These compounds exhibited favorable binding affinities and demonstrated desirable drug-like properties. Molecular dynamics simulations confirmed stable protein-ligand interactions. These findings suggest that CNP0375130 and CNP0256178 may serve as promising lead compounds for the development of novel anti-leukemic therapies targeting DNMT3A, and contribute to the ongoing efforts to develop targeted therapies for leukemia.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.